Cargando…
Ace revisited: A new target for structure-based drug design
Current-generation angiotensin-converting enzyme (ACE) inhibitors are widely used for cardiovascular diseases, including high blood pressure, heart failure, heart attack and kidney failure, and have combined annual sales in excess of US $6 billion. However, the use of these ACE inhibitors, which wer...
Autores principales: | Acharya, K. Ravi, Sturrock, Edward D., Riordan, James F., Ehlers, Mario R. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097707/ https://www.ncbi.nlm.nih.gov/pubmed/14668810 http://dx.doi.org/10.1038/nrd1227 |
Ejemplares similares
-
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV
por: Lubbe, Lizelle, et al.
Publicado: (2020) -
ACE-domain selectivity extends beyond direct interacting residues at the active site
por: Cozier, Gyles E., et al.
Publicado: (2020) -
Crystal structures of sampatrilat and sampatrilat‐Asp in complex with human ACE – a molecular basis for domain selectivity
por: Cozier, Gyles E., et al.
Publicado: (2018) -
Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides
por: Masuyer, Geoffrey, et al.
Publicado: (2012) -
Molecular and Thermodynamic Mechanisms of the Chloride-dependent Human Angiotensin-I-converting Enzyme (ACE)
por: Yates, Christopher J., et al.
Publicado: (2014)